Vectibix Caution For Usage

Special precautions for disposal and other handling: Panitumumab (Vectibix) is intended for single-use only. Panitumumab (Vectibix) should be diluted in sodium chloride 9 mg/mL (0.9%) solution for injection by healthcare professional using aseptic technique. Do not shake or vigorously agitate the vial. Panitumumab (Vectibix) should be inspected visually prior to administration. The solution should be colourless and may contain visible translucent-to-white, amorphous, proteinaceous particulates (which will be removed by in-line filtration). Do not administer Panitumumab (Vectibix) if its appearance is not as described as previously mentioned. Using only a 21-gauge or smaller diameter hypodermic needle, withdraw the necessary amount of Panitumumab (Vectibix) for a dose of 6 mg/kg. Do not use needle-free devices (e.g. vial adapters) to withdraw vial contents. Dilute in a total volume of 100 mL. The final concentration should not exceed 10 mg/mL. Doses higher than 1,000 mg should be diluted in 150 mL sodium chloride 9 mg/mL (0.9%) solution for injection (see Dosage & Administration). The diluted solution should be mixed by gentle inversion, do not shake.
Panitumumab (Vectibix) must be administered using a low protein binding 0.2 or 0.22 micrometre in-line filter, through a peripheral line or indwelling catheter.
No incompatibilities have been observed between Panitumumab (Vectibix) and sodium chloride 9 mg/mL (0.9%) solution for injection in polyvinyl chloride bags or polyolefin bags.
Discard the vial and any liquid remaining in the vial after the single-use.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Incompatibilities: This medicinal product must not be mixed with other medicinal products except those mentioned under Description.